Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet Victor G. Martinez et al, 2019, Frontiers in Genetics CrossRef
DUB3 Facilitates Growth and Inhibits Apoptosis Through Enhancing Expression of EZH2 in Oral Squamous Cell Carcinoma
Fei Luo et al, 2020, OncoTargets and Therapy CrossRef
The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway Linping Lei et al, 2021, Investigational New Drugs CrossRef
Privileged Scaffolds Targeting Bromodomain-containing Protein 4 Ru Wang et al, 2022, Current Topics in Medicinal Chemistry CrossRef
From Therapy Resistance to Targeted Therapies in Prostate Cancer Filipa Moreira-Silva et al, 2022, Frontiers in Oncology CrossRef
Physachenolide C is a Potent, Selective BET Inhibitor Christopher J. Zerio et al, 2023, Journal of Medicinal Chemistry CrossRef
High Expression Level of BRD4 Is Associated with a Poor Prognosis and Immune Infiltration in Esophageal Squamous Cell Carcinoma Li Li et al, 2023, Digestive Diseases and Sciences CrossRef
BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4 Hae In Choi et al, 2021, Scientific Reports CrossRef
MiR-21-3p Plays a Crucial Role in Metabolism Alteration of Renal Tubular Epithelial Cells during Sepsis Associated Acute Kidney Injury via AKT/CDK2-FOXO1 Pathway Zhuoyong Lin et al, 2019, BioMed Research International CrossRef
A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression Zijun Zhou et al, 2020, Frontiers in Pharmacology CrossRef
Identification and Validation of a Prognostic 5-Protein Signature for Biochemical Recurrence Following Radical Prostatectomy for Prostate Cancer Daojun Lv et al, 2021, Frontiers in Surgery CrossRef